Citations

Clear

815 citation(s) found for "Tang, Yu".

P1‐311: DEVELOPMENT OF AN INTERNATIONAL POSTERIOR CORTICAL ATROPHY BIOREGISTRY
Pelak, Victoria S. , Tang‐Wai, David F. , Onyike, Chiadi U. , Olds, Jennifer, Hills, William L., Bretsch, Candace, Lusk, Jerri, Boyd, Timothy, Pressman, Peter , Holden, Samantha K. , Bettcher, Bri M., Bouwman, Femke H. , Murray, Melissa E. , Day, Gregory S. , Migliaccio, Raffaella Lara , Potter, Huntington , Boyd, Timothy D.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2019.06.866 Get It

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
Parikh, Kejal , Abouzaid, Safiya, Zhou, Zhou , Clancy, Zoe, Cheung, Claudia , Zhou, Zheng‐Yi , Xie, Jipan , Ailawadhi, Sikander , Tang, Wenxi

Mayo Clinic

Blood Advances | October 17, 2019 | Volume: 3 | Issue: 20 | Pages: 2986-2994

10.1182/bloodadvances.2019000308 | PMID 31648322 Get It

Abstract The objective of the study was to assess racial disparities in the treatment and outcomes among white, African American, and Hispanic patients with multiple myeloma (MM). Patients with an MM diagnosis from the Surveillance Epidemiology and End Results (SEER)–Medicare (2007-2013) database were included. Continuous Medicare enrollment for 6 months before (baseline) and after MM diagnosis was required unless death occurred. Time from MM diagnosis to novel therapy initiation and autologous stem cell transplant (ASCT), overall survival (OS), and MM-specific survival (MSS) was evaluated. Unadjusted and multivariable regressions compared African Americans and Hispanics vs whites. Trends of novel therapy and ASCT use across MM diagnosis years were assessed using linear regression models. The study included 3504 whites, 858 African Americans, and 468 Hispanics. African Americans and Hispanics had a longer time from MM diagnosis to novel therapy initiation vs whites (median: 5.2 and 4.6 vs 2.7 months, respectively). All cohorts had an increasing trend of novel therapy initiation within 6 months of MM diagnosis, particularly whites (all P < .05). Median MSS was significantly longer for African Americans (5.4 years) than whites (4.5 years; P < .05), and was comparable for Hispanics and whites. Median OS was similar overall (2.6-2.8 years). ASCT rate within 1 year of MM diagnosis rose among whites and African Americans (P < .05), but not Hispanics, who were less likely to receive ASCT vs whites. Significant variations in novel therapy and ASCT use were observed among different racial/ethnic groups with MM. Although OS was similar, both African Americans and Hispanics may not be fully benefitting from the introduction of novel therapies, as they receive them later than whites.
Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion
Xiu, Yan , Dong, Qianze , Fu, Lin , Bossler, Aaron , Tang, Xiaobing , Borcherding, Nicholas , Leidinger, Mariah , Sardina, José Luis , Li, Qingchang , Aifantis, Iannis , Boccalatte, Francesco , Wang, Lili , Jin, Meiling , Khoury, Joseph D. , Wang, Wei , Hu, Shimin , Yuan, Youzhong , Wang, Endi , Ji, Yuan , Janz, Siegfried , Colgan, John , Habelhah, Hasem , Waldschmidt, Thomas J. , Müschen, Markus , Bagg, Adam , Feldman, Andrew, Hu, Shimin , Borcherding, Nicholas , Janz, Siegfried , Yuan, Ji , Boyce, Brendan F. , Xue, Hai‐Hui , Feldman, Andrew L. , Darbro, Benjamin W. , Zhao, Chen

Mayo Clinic

Blood | October 14, 2019 | Volume: 135 | Issue: 2 | Pages: 108-120

10.1182/blood.2019001438 | PMID 31697816 Get It

AbstractNF-κB and Notch signaling can be simultaneously activated in a variety of B-cell lymphomas. Patients with B-cell lymphoma occasionally develop clonally related myeloid tumors with poor prognosis. Whether concurrent activation of both pathways is sufficient to induce B-cell transformation and whether the signaling initiates B-myeloid conversion in a pathological context are largely unknown. Here, we provide genetic evidence that concurrent activation of NF-κB and Notch signaling in committed B cells is sufficient to induce B-cell lymphomatous transformation and primes common progenitor cells to convert to myeloid lineage through dedifferentiation, not transdifferentiation. Intriguingly, the converted myeloid cells can further transform, albeit at low frequency, into myeloid leukemia. Mechanistically, coactivation of NF-κB and Notch signaling endows committed B cells with the ability to self renew. Downregulation of BACH2, a lymphoma and myeloid gene suppressor, but not upregulation of CEBPα and/or downregulation of B-cell transcription factors, is an early event in both B-cell transformation and myeloid conversion. Interestingly, a DNA hypomethylating drug not only effectively eliminated the converted myeloid leukemia cells, but also restored the expression of green fluorescent protein, which had been lost in converted myeloid leukemia cells. Collectively, our results suggest that targeting NF-κB and Notch signaling will not only improve lymphoma treatment, but also prevent the lymphoma-to-myeloid tumor conversion. Importantly, DNA hypomethylating drugs might efficiently treat these converted myeloid neoplasms.
Renal Artery Stenosis Alters Gene Expression in Swine Scattered Tubular-Like Cells
Nargesi, Arash Aghajani , Zhu, Xiang-Yang, Liu, Yuanhang , Jordan, Kyra L., Lerman, Lilach O. , Eirin, Alfonso , Aghajani Nargesi, Arash, Lerman, Lilach O , Eirin, Alfonso , Tang, Hui Jun

Mayo Clinic

International Journal of Molecular Sciences | October 14, 2019 | Volume: 20 | Issue: 20 | Pages: 5069

10.3390/ijms20205069 | PMID 31614781 Get It

Background: Scattered tubular-like cells (STCs) proliferate and differentiate to support neighboring injured renal tubular cells during recovery from insults. Renal artery stenosis (RAS) induces renal ischemia and hypertension and leads to loss of kidney function, but whether RAS alters renal endogenous repair mechanisms, such as STCs, remains unknown. We hypothesize that RAS in swine modifies the messenger RNA (mRNA) profile of STCs, blunting their in vitro reparative capacity. Methods: CD24+/CD133+ STCs were isolated from pig kidneys after 10-weeks of RAS or sham (n = 3 each) and their gene cargo analyzed using high-throughput mRNAseq. Expression profiles for upregulated and downregulated mRNAs in RAS-STCs were functionally interpreted by gene ontology analysis. STC activation was assessed by counting the total number of STCs in pig kidney sections using flow cytometry, whereas cell proliferation was assessed in vitro. Results: Of all expressed genes, 1430 genes were upregulated and 315 downregulated in RAS- versus Normal-STCs. Expression of selected candidate genes followed the same fold change directions as the mRNAseq findings. Genes upregulated in RAS-STCs were involved in cell adhesion, extracellular matrix remodeling, and kidney development, whereas those downregulated in RAS-STCs are related to cell cycle and cytoskeleton. The percentage of STCs from dissociated kidney cells was higher in RAS versus Normal pigs, but their proliferation rate was blunted. Conclusions: Renal ischemia and hypertension in swine induce changes in the mRNA profile of STCs, associated with increased STC activation and impaired proliferation. These observations suggest that RAS may alter the reparative capacity of STCs.
A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas
Hui, Tang, Micallef, Ivana N. , Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Johnston, Patrick B. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Allmer, Cristine, Hohl, Raymond J., Kurtin, Paul J. , Ding, Husheng, David, Loegering A, Schneider, Paula A., Peterson, Kevin L. , Witzig, Thomas E. , Hui, Tang, Link, Brian K. , Colgan, Joseph P. , Markovic, Svetomir N. , Maurer, Matthew J. , Weiner, George J. , Habermann, Thomas M. , Kaufmann, Scott H.

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: 287-287

10.1182/blood.v116.21.287.287 Get It

Abstract Abstract 287 Purpose: Farnesyltransferases are key cellular enzymes involved in the prenylation of proteins. Prenylated proteins are important for malignant cell growth. The purpose of this phase II study (NCT00082888) was to assess tumor response and toxicity associated with the oral farnesyltransferase inhibitor tipifarnib (R115777, Johnson and Johnson) in patients with relapsed aggressive, indolent, or uncommon lymphoma. The uncommon group included low incidence lymphoma types such as Hodgkin lymphoma (HL) and T-cell non-Hodgkin lymphoma- cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Patients and Methods: Patients with relapsed or refractory non-Hodgkin (NHL) or Hodgkin (HL) were eligible if they had measurable disease, performance status ≤2, platelet count ≥75,000 × 10(6)/L, an absolute neutrophil count ≥1000 × 10(6)/L and a creatinine ≤2 × upper limit of normal. Patients initially received tipifarnib 300 mg twice daily, days 1–21 every 28 days. The trial was conducted by the University of Iowa/Mayo Clinic Lymphoma SPORE. Results: Ninety-three patients with lymphoma (42 aggressive, 15 indolent, and 36 uncommon) enrolled in the trial between March 2004 and November 2008. The median age was 62 years (range, 18–91). The median number of prior therapies was 5 (range, 1–17). The overall response rate (ORR) was 20% (19/93) with 6% (6/93) complete responses (CR) and 14% (13/93) partial responses (PR). The ORR was 17%, 7%, and 31% for the aggressive, indolent, and uncommon groups, respectively (Table). Among the 19 responders were 7 diffuse large B-cell lymphoma (DLBCL), 7 T-cell NHL, 1 follicular grade II, and 4 HL. The overall median response duration for the 19 responders was 7.5 months (mean, 12.8; range, 1.8 – 48.1 months). The median response duration was 11.3 months (mean, 10.1; range, 1.8 – 18.5 months), 2 months, and 7.5 months (mean, 15.5; range, 1.9 – 48.1 months) for the aggressive (7), indolent (1), and uncommon (11) groups, respectively. Five patients in the uncommon group are still receiving treatment with a range of treatment duration between 25 – 60+ months. Among the 5 still receiving treatment 4 responded and 1 is stable. The range of response duration is 15.4, 17.7, 43.1, and 48.1 months. These five patients (2 with HL, 1 anaplastic large cell cutaneous, and 2 PTCL) are currently receiving doses of 400 (1), 200 (2), and 100 (2) mg twice daily. The median time to progression for all patients was 3.6 months (95% CI: 2.1 – 4.5 months). The grade 3,4 toxicities observed were primarily fatigue (10%) and reversible myelosuppression with 11% anemia, 37% neutropenia, and 32% thrombocytopenia. Correlative studies demonstrated tipifarnib-induced upregulation of Bim, a marker of tipifarnib action in lymphoma cell lines, in 7 of 9 paired lymphoma biopsies. Conclusions: Tipifarnib has activity in lymphoma, with responses in patients with heavily pretreated DLBCL, HL and T-cell types, but little activity in follicular NHL. This agent has an excellent toxicity profile and targets a novel pathway. Further studies in combination with other agents are warranted for patients with DLBCL, HL or T-cell NHL. Disclosures: No relevant conflicts of interest to declare.
Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma
Ansell, Stephen M. , Nowakowski, Grzegorz S. , Nikcevich, Daniel A., Nelson, Garth D. , Erlichman, Charles , Group, North Central Cancer Treatment, Tang, Hui Jun , Witzig, Thomas E. , Group, North Central Cancer Treatment

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: 2862-2862

10.1182/blood.v116.21.2862.2862 Get It

Abstract Abstract 2862 Follicular lymphoma (FL) is a B-cell malignancy that exhibits significant intratumoral infiltration by non-malignant T lymphocytes. The pathophysiological significance of infiltrating T cells is poorly understood but recent studies have suggested that CD4+CD25+ regulatory T (Treg) cells are highly represented in lymph nodes involved by FL. These Treg cells display the ability to suppress the proliferation and cytokine production of other tumor-infiltrating T cells and migrate to areas of B-cell lymphoma in response to chemotactic signals provided by the malignant B-cells. Denileukin diftitox, a chimeric immunotoxin composed of the modified cytotoxic domain of diphtheria toxin and human interleukin-2 (IL-2) protein, targets cells expressing CD25 and has proven efficacy in patients with relapsed B-cell lymphoma. In this study, we combined denileukin diftitox with rituximab in a cohort of previously untreated, advanced-stage follicular lymphoma patients. Our hypothesis was that denileukin diftitox would deplete the Treg cells, thereby removing the inhibition of the immune response, and rituximab would deplete the B-cells thereby preventing further recruitment of Treg cells to the areas of lymphoma. Between August 2008 and March 2010, twenty-four patients with stage III and IV follicular grade 1 or 2 non-Hodgkin lymphoma were accrued to the study. One patient died before treatment was given and is not included in the analysis. The median age was 60 years (range: 27 – 79), 12 (52%) of the patients were male, 19 (83%) had a PS of 0 and 4 (17%) had a PS of 1. Based on the Follicular Lymphoma International Prognostic Index (FLIPI), 3 (13%) were low risk, 14 (61%) were intermediate risk and 6 (26%) were high risk. Patients received rituximab 375 mg/m2 on days 1, 8, 15 and 22 and denileukin diftitox 18 mcg/kg/day on days 1–5 every 3 weeks for 4 cycles. A median of 4 cycles of therapy was given (range: 1 – 4). Thirteen patients completed treatment per protocol (57%), however 5 patients discontinued treatment due to adverse events (22%), 2 refused further treatment (9%) and 1 discontinued due to disease progression (4%). Nine of the 23 patients (39%; 95% CI: 21–61%) responded to treatment, 3 (13%) had a complete response and 6 (26%) had a partial response. Twenty-one patients (91%) are alive with a median follow-up of 8.7 months (range: 3.4–19.5). Seven (30%) patients have progressed and two (8.7%) has died. The median time to progression is 13.4 months (95% CI: 10.4 – NA). The combination, however, was associated with significant toxicity. Thirteen patients (57%) experienced grade 3 or greater adverse events. Six patients (26%) had symptoms of capillary leak syndrome, 1 of whom died. In correlative studies performed on the peripheral blood, the number of CD25+ T-cells decreased after treatment when compared to pretreatment numbers (median 24%; range: 8–44%). We conclude that while the addition of denileukin diftitox to rituximab decreased the numbers of CD25+ T-cells, denileukin diftitox contributed significantly to the toxicity of the combination. Furthermore, the overall response rate and time to progression in this study were no better than what would be expected in follicular lymphoma patients treated with rituximab alone. Disclosures: No relevant conflicts of interest to declare.
A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
Ansell, Stephen M. , Kurtin, Paul J. , Koenig, Patricia, Inwards, David J. , Shah, Keith, Tang, Hui Jun , Witzig, Thomas E.

Mayo Clinic

Blood | October 9, 2019 | Volume: 114 | Issue: 22 | Pages: 1665-1665

10.1182/blood.v114.22.1665.1665 Get It

Abstract Abstract 1665 Poster Board I-691 Mantle cell lymphoma (MCL) is an aggressive, incurable B-cell malignancy that represents approximately 6% of lymphoma cases. Patients with MCL who relapse after conventional therapy or stem cell transplantation have a poor prognosis and are candidates for treatment with novel agents. The characteristic feature of MCL is overexpression of cyclin D1. Cyclin D1 is under the control of the phosphatidylinositol-3 kinase signal-transduction pathway and is downstream of the mammalian target of rapamycin kinase (mTOR). We have previously shown that temsirolimus (CCI-779), a dihydroester of the selective mTOR inhibitor rapamycin, is an active antitumor agent in MCL. In previous phase 2 trials of temsirolimus as a single agent, we observed a 40% overall response rate (ORR) with a median duration of response (DR) of 6 months in patients with relapsed or refractory disease (J Clin Oncol 23:5347-56, 2005; Cancer 113:508-514, 2008). Due to the fact that rituximab has improved the response rate and overall outcome of lymphoma patients when combined with chemotherapy, we tested the efficacy and toxicity of temsirolimus in combination with rituximab in patients with MCL. Eligible patients with confirmed relapsed or refractory MCL based on morphologic and phenotypic features received temsirolimus 25 mg intravenously every week and four weekly doses of rituximab with the first cycle and then one dose of rituximab every other cycle. Patients with a tumor response after six cycles were eligible to continue treatment for a total of 12 cycles or two cycles after complete remission, and were then observed without maintenance. Seventy-one patients were enrolled between May 2005 and March 2009. The median age was 67 years (range, 44 to 86 years), with 51 males and 20 females enrolled. Patients had received a median of two prior therapies (range, 1-9), 31% had received a prior stem cell transplant and 28% were rituximab refractory. The ORR was 48% (34/71 patients) with 20% (14/71) complete responses and 28% (20/71) partial responses. The median DR was 9.5 months (95% CI, 4.5 to 11.3 months). The median DR in the rituximab sensitive patients was 9.5 months (CI: 4.5-11.6) and 7.15 months (CI: 4.1-11.3) in the rituximab refractory patients (p= 0.73). While the combination was generally well tolerated, 12 patients experienced grade 4 toxicity and 2 patients died while on therapy – both from progressive disease. Hematologic toxicities were the most common, with 5 patients having grade 4 thrombocytopenia and 3 having grade 4 neutropenia. This study demonstrates that temsirolimus in combination with rituximab is well tolerated and has substantial antitumor activity in relapsed MCL. Further comparative studies of this combination in MCL are therefore warranted. Disclosures Witzig: Wyeth: Patents & Royalties.
Ethics of Artificial Intelligence in Radiology: Summary of the Joint European and North American Multisociety Statement
Geis, J. Raymond , Brady, Adrian P. , Spencer, Jack , Ranschaert, Erik , Jaremko, Jacob L. , Langer, Steve G., Birch, Judy, Shields, William , Genderen, R. van den Hoven van , Cook, Tessa S. , Morgan, Matthew B. , Tang, An , Safdar, Nabile , Wu, Carol C. , Langer, Steve G., Kitts, Andrea Borondy , Birch, Judy, Shields, William F., Kotter, Elmar , Gichoya, Judy Wawira , Kohli, Marc

Mayo Clinic

Canadian Association of Radiologists Journal | October 1, 2019 | Volume: 70 | Issue: 4 | Pages: 329-334

10.1016/j.carj.2019.08.010 | PMID 31585825 Get It

This is a condensed summary of an international multisociety statement on ethics of artificial intelligence (AI) in radiology produced by the ACR, European Society of Radiology, RSNA, Society for Imaging Informatics in Medicine, European Society of Medical Imaging Informatics, Canadian Association of Radiologists, and American Association of Physicists in Medicine. AI has great potential to increase efficiency and accuracy throughout radiology, but it also carries inherent pitfalls and biases. Widespread use of AI-based intelligent and autonomous systems in radiology can increase the risk of systemic errors with high consequence and highlights complex ethical and societal issues. Currently, there is little experience using AI for patient care in diverse clinical settings. Extensive research is needed to understand how to best deploy AI in clinical practice. This statement highlights our consensus that ethical use of AI in radiology should promote well-being, minimize harm, and ensure that the benefits and harms are distributed among stakeholders in a just manner. We believe AI should respect human rights and freedoms, including dignity and privacy. It should be designed for maximum transparency and dependability. Ultimate responsibility and accountability for AI remains with its human designers and operators for the foreseeable future. The radiology community should start now to develop codes of ethics and practice for AI that promote any use that helps patients and the common good and should block use of radiology data and algorithms for financial gain without those two attributes.
The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection
Asbun, Horacio J. , Moekotte, Alma , Vissers, Frederique L., Kunzler, F. , Cipriani, Federica , D’Angelica, Michael I. , Balduzzi, Alberto , Bassi, Claudio , Björnsson, Bergþór , Boggi, Ugo , Callery, Mark P., Chiaro, Marco Del , Coimbra, Felipe José Fernández , Conrad, Claudius , Cook, Andrew , Coppola, Alessandro , Dervenis, Christos, Dokmak, Safi , Edil, Barish H. , Giulianotti, Pier Cristoforo , Hansen, Paul D., Heijde, Nicky van der , Hilst, Jony van , Hester, Caitlin A. , Hogg, Melissa E. , Jarufe, Nicolás , Jeyarajah, D. Rohan, Kim, Song Cheol, Khatkov, Igor , Kokudo, Norihiro , Kooby, David A. , Korrel, Maarten , Leon, Francisco J. de, Lluís, Núria , Lof, Sanne , Demartines, Nicolas , Merchant, Nipun B. , Molenaar, I. Quintus, Moravek, Cassadie, Mou, Yiping , Nealon, William H. , Palanivelu, Chinnusamy, Pessaux, Patrick , Pitt, Henry A. , Primrose, John N., Rawashdeh, Arab , Sanford, Dominic E. , Senthilnathan, Palanisamy, Shrikhande, Shailesh V. , Stauffer, John , Takaori, Kyoichi , Tang, Chung Ngai, Vollmer, Charles M., Wakabayashi, Go , Walsh, R. Matthew , Wang, Shin-E, Zinner, Michael J. , Wolfgang, Christopher L. , Zureikat, Amer H. , Zwart, M. , Conlon, Kevin C. , Kendrick, Michael L., Zeh, Herbert J. , Hilal, Mohammad Abu, Besselink, Marc G. , Primrose, John , Hilal, Mohammad Abu , Demartines, N , A Stauffer, John , Alseidi, Adnan A. , Edwin, Bjørn , Han, Ho-Seong , Jeyarajah, D. Rohan , Keck, Tobias , Machado, Marcel Autran C. , Martinie, John B. , Moravek, Cassadie, Nakamura, Masafumi , Palanivelu, Chinnusamy , Polanco, Patricio Marcelo , Talamonti, Marina , Wang, Shin‐E , Kendrick, Michael L. , Besselink, Marc G , Cipriani, Federica

Mayo Clinic

Annals of Surgery | September 22, 2019 | Volume: 271 | Issue: 1 | Pages: 1-14

10.1097/sla.0000000000003590 | PMID 31567509 Get It

Objective: The aim of this study was to develop and externally validate the first evidence-based guidelines on minimally invasive pancreas resection (MIPR) before and during the International Evidence-based Guidelines on Minimally Invasive Pancreas Resection (IG-MIPR) meeting in Miami (March 2019). Summary Background Data: MIPR has seen rapid development in the past decade. Promising outcomes have been reported by early adopters from high-volume centers. Subsequently, multicenter series as well as randomized controlled trials were reported; however, guidelines for clinical practice were lacking. Methods: The Scottisch Intercollegiate Guidelines Network (SIGN) methodology was used, incorporating these 4 items: systematic reviews using PubMed, Embase, and Cochrane databases to answer clinical questions, whenever possible in PICO style, the GRADE approach for assessment of the quality of evidence, the Delphi method for establishing consensus on the developed recommendations, and the AGREE-II instrument for the assessment of guideline quality and external validation. The current guidelines are cosponsored by the International Hepato-Pancreato-Biliary Association, the Americas Hepato-Pancreato-Biliary Association, the Asian-Pacific Hepato-Pancreato-Biliary Association, the European-African Hepato-Pancreato-Biliary Association, the European Association for Endoscopic Surgery, Pancreas Club, the Society of American Gastrointestinal and Endoscopic Surgery, the Society for Surgery of the Alimentary Tract, and the Society of Surgical Oncology. Results: After screening 16,069 titles, 694 studies were reviewed, and 291 were included. The final 28 recommendations covered 6 topics; laparoscopic and robotic distal pancreatectomy, central pancreatectomy, pancreatoduodenectomy, as well as patient selection, training, learning curve, and minimal annual center volume required to obtain optimal outcomes and patient safety. Conclusion: The IG-MIPR using SIGN methodology give guidance to surgeons, hospital administrators, patients, and medical societies on the use and outcome of MIPR as well as the approach to be taken regarding this challenging type of surgery.
Gene Expression and Missplicing in the Corneal Endothelium of Patients With a TCF4 Trinucleotide Repeat Expansion Without Fuchs' Endothelial Corneal Dystrophy
Wieben, Eric D. , Baratz, Keith H. , Aleff, Ross A., Maguire, Leo J., Fautsch, Michael P. , Kalari, Krishna R. , Tang, Xiaojia , Patel, Sanjay V.

Mayo Clinic

Investigative Opthalmology & Visual Science | August 30, 2019 | Volume: 60 | Issue: 10 | Pages: 3636

10.1167/iovs.19-27689 | PMID 31469403 Get It